[go: up one dir, main page]

MX2020009920A - Tratamiento y profilaxis de amiloidosis. - Google Patents

Tratamiento y profilaxis de amiloidosis.

Info

Publication number
MX2020009920A
MX2020009920A MX2020009920A MX2020009920A MX2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A MX 2020009920 A MX2020009920 A MX 2020009920A
Authority
MX
Mexico
Prior art keywords
treatment
amyloidosis
prophylaxis
antibody
deposition
Prior art date
Application number
MX2020009920A
Other languages
English (en)
Inventor
Robin Barbour
Tarlochan Nijjar
Iii Philip J Dolan
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2020009920A publication Critical patent/MX2020009920A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para el tratamiento de la amiloidosis AL asociada con el depósito de proteínas de cadena ligera de inmunoglobulina mal plegadas y sus usos correspondientes relacionados con un anticuerpo, tal como un anticuerpo 2A4, o una formulación farmacéutica que comprende el anticuerpo.
MX2020009920A 2018-03-23 2019-03-22 Tratamiento y profilaxis de amiloidosis. MX2020009920A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (1)

Publication Number Publication Date
MX2020009920A true MX2020009920A (es) 2020-12-10

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009920A MX2020009920A (es) 2018-03-23 2019-03-22 Tratamiento y profilaxis de amiloidosis.

Country Status (13)

Country Link
US (1) US20210017278A1 (es)
EP (1) EP3768311A1 (es)
JP (1) JP7217287B2 (es)
KR (1) KR20200143400A (es)
CN (1) CN112040983A (es)
AU (2) AU2019240413A1 (es)
BR (1) BR112020019172A2 (es)
CA (1) CA3095100A1 (es)
EA (1) EA202092264A1 (es)
MX (1) MX2020009920A (es)
MY (1) MY203432A (es)
SG (1) SG11202009295YA (es)
WO (1) WO2019183448A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102016059B (zh) * 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
MX391043B (es) 2011-10-25 2025-03-21 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
RS63446B1 (sr) * 2016-06-30 2022-08-31 Prothena Biosciences Ltd Kompozicije za lečenje amiloidoze

Also Published As

Publication number Publication date
CA3095100A1 (en) 2019-09-26
SG11202009295YA (en) 2020-10-29
EP3768311A1 (en) 2021-01-27
US20210017278A1 (en) 2021-01-21
BR112020019172A2 (pt) 2021-01-26
KR20200143400A (ko) 2020-12-23
AU2019240413A1 (en) 2020-10-08
WO2019183448A1 (en) 2019-09-26
AU2023202109A1 (en) 2023-05-18
JP2021518393A (ja) 2021-08-02
JP7217287B2 (ja) 2023-02-02
MY203432A (en) 2024-06-27
EA202092264A1 (ru) 2020-12-03
CN112040983A (zh) 2020-12-04

Similar Documents

Publication Publication Date Title
AR132864A2 (es) UN ANTICUERPO QUE SE UNE ESPECÍFICAMENTE A a-SINUCLEÍNA HUMANA, UN ANTICUERPO HUMANIZADO, UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE EL ANTICUERPO, Y LA UTILIZACIÓN DEL ANTICUERPO
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
CO2019009680A2 (es) Anticuerpo anti-gprc5d y molécula que comprende el anticuerpo
ECSP21033236A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
MX2017006626A (es) Cadenas ligeras comunes y metodos de uso.
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
MX2019012978A (es) Composiciones para el cuidado bucal y metodos para utilizar las composiciones.
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
AR114565A1 (es) Proteínas de fusión fc il-22 y métodos de uso
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2020003581A (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
EP3884663A4 (en) MULTI-WAVELENGTH VISIBLE LASER SOURCE
CL2018003838S1 (es) Botella.
MX2019012865A (es) Anticuerpos anti-interferon gamma y usos de los mismos.
DOP2021000021A (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ECSP19026702A (es) Compuestos novedosos para el tratamiento de enfermedades parasitarias
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
MX2021004774A (es) Formulacion de anticuerpos.
CO2021010786A2 (es) Toxinas apxia, apxiia y apxiiia inactivadas
CO2017002614A2 (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
AR108148A1 (es) Métodos para recubrir superficies de empaque con compuestos de benzoxaborol para preservar la frescura de los alimentos